NCT04877132Approved For Marketing不适用
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Sanofi
研究概览
简要总结
The objective of this program is to provide access to enzyme replacement therapy (ERT) with olipudase alfa for certain patients with ASMD, a severe, life threatening disease, that could not participate in the olipudase clinical trials. The program will provide access to olipudase alfa prior to registration and the availability of commercial product (including reimbursement where applicable) in the country of the patient.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients (adult and pediatric)
- •Unsolicited request for the patient from a site with at least 3 years of experience in administration and safety management of ERT.
- •Written informed consent signed by the patient or the patient's parent(s)/guardian(s), where applicable.
- •Documented deficiency of acid sphingomyelinase in peripheral leukocytes, lymphocytes, or cultured fibroblasts.
- •Adult patients
- •Age ≥ 18 years.
- •Clinically documented advanced disease evidenced by defined thresholds for lung, spleen, liver, and hematologic parameters.
- •Pediatric patients
- •Age >3 years and <18 years or clinical diagnosis consistent with ASMD Type A/B or Type B.
排除标准
- •All patients (adult and pediatric)
- •Active serious intercurrent illness which will preclude enrollment, significant liver disease with etiology other than ASMD, Malignancy with poor prognosis, serious medical or psychiatric condition that may preclude participation, or circumstances that may interfere with compliance in this compassionate use program, requirement for recurrent dose adjustment of anticoagulation treatment over the last 6 months.
- •Pregnancy or breastfeeding.
- •For female patients of childbearing potential, a positive serum pregnancy (β human chorionic gonadotropin [HCG]) test result.
- •For female patients of childbearing potential and sexually active male patients, unwillingness to abstain from heterosexual intercourse in accordance with their preferred and usual lifestyle, or to use 2 acceptable, effective contraceptive methods, while participating in this program and for 15 days after the last infusion of olipudase alfa.
- •For pediatric patients, clinical diagnosis, or suspicion of infantile onset ASMD. Genotype compatible with ASMD type A.
研究者
相似试验
No Longer Available
不适用
Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic SeizuresEpilepsies, PartialNCT03559673UCB Biopharma S.P.R.L.
No Longer Available
不适用
Early Patient Access Treatment Use Protocol CA204-220Multiple MyelomaNCT02856438Bristol-Myers Squibb
No Longer Available
不适用
Expanded Access Treatment Protocol CA204-143Multiple MyelomaNCT02368301Bristol-Myers Squibb
No Longer Available
不适用
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple SclerosisNCT02807285Genentech, Inc.
Available
不适用
Named Patient Program for Olverembatinib (HQP1351)NCT05594758Ascentage Pharma Group Inc.